The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).
 
Lu Si
Honoraria - MSD; Novartis; Oriengene; Roche China; Shanghai Junshi Biosciences
 
Caili Li
No Relationships to Disclose
 
Xue Bai
Other Relationship - Bristol-Myers Squibb
 
Li Zhou
No Relationships to Disclose
 
Lili Mao
Honoraria - MSD; Novartis; Shanghai Junshi BioSciences
 
Chuanliang Cui
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
BIN LIAN
No Relationships to Disclose
 
Xuan Wang
No Relationships to Disclose
 
Bixia Tang
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Siming Li
No Relationships to Disclose
 
Yan Kong
No Relationships to Disclose
 
Jie Dai
No Relationships to Disclose
 
Xiaoting Wei
No Relationships to Disclose
 
Juan Li
No Relationships to Disclose
 
Fan Yang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Zheng Pang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere